Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Institutional investor adds to stake in biopharmaceutical company

Apr. 13, 2026 at 8:09am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up photograph of the complex machinery and mechanisms that power the pharmaceutical industry, conveying a sense of institutional strength and financial infrastructure.An extreme close-up of the inner workings of the pharmaceutical industry, symbolizing the institutional investments and financial mechanisms driving innovation and growth.Tarrytown Today

Burney Co., an institutional investor, acquired a new stake of 3,487 shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to a recent SEC filing. The shares were valued at approximately $2.7 million.

Why it matters

Regeneron Pharmaceuticals is a major player in the biopharmaceutical industry, known for its innovative drug discovery technologies. This acquisition by Burney Co. signals continued investor confidence in the company's growth potential and future performance.

The details

According to the 13F filing, Burney Co. bought the 3,487 shares of Regeneron Pharmaceuticals in the fourth quarter. This represents a new stake for the institutional investor in the biopharmaceutical company.

  • Burney Co. acquired the new shares in Regeneron Pharmaceuticals during the fourth quarter.

The players

Burney Co.

An institutional investor that acquired a new stake in Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This acquisition by Burney Co. reflects ongoing investor interest in Regeneron Pharmaceuticals, a leading biopharmaceutical company known for its innovative drug discovery technologies. The move signals confidence in Regeneron's growth potential and future performance.